Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 5/20 | 0.51 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.43 |
| ▸ | CPB2 | Q96IY4 | 6/20 | 0.40 |
| ▸ | GNPAT | O15228 | 2/20 | 0.40 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.39 |
| ▸ | GSR | P00390 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
| ▸ | CPB1 | P15086 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9716637 | 1.00 | FOLH1 (0.51) | FOLH1SLC6A5CPB2GNPATNOD1 | |
| SCHEMBL9716635 | 1.00 | FOLH1 (0.51) | FOLH1SLC6A5CPB2GNPATNOD1 | |
| SCHEMBL9698704 | 0.95 | FOLH1 (0.58) | FOLH1SLC6A5CPB2GSRCA1 | |
| SCHEMBL3435138 | 0.95 | FOLH1 (0.58) | FOLH1SLC6A5CPB2GSRCA1 | |
| Hydrochloric Acid SCHEMBL31741284 | 0.93 | FOLH1 (0.57) | FOLH1SLC6A5CPB2GSRCA1 | |
| SCHEMBL2628236 | 0.89 | GABRR1 (0.43) | FOLH1SLC6A5TGFBR1 | |
| SCHEMBL27966321 | 0.85 | FOLH1 (0.40) | FOLH1GNPATNOD1TGFBR1 | |
| SCHEMBL9716665 | 0.84 | FOLH1 (0.47) | FOLH1SLC6A5CPB2NOD1 | |
| SCHEMBL9716671 | 0.84 | FOLH1 (0.47) | FOLH1SLC6A5CPB2NOD1 | |
| SCHEMBL9716663 | 0.84 | FOLH1 (0.47) | FOLH1SLC6A5CPB2NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099061-A1 | SYNTHESIS OF CAROTENOID ANALOGS OR DERIVATIVES WITH IMPROVED ANTIOXIDANT CHARACTERISTICS | CARDAX PHARMACEUTICALS, INC. | 2009-04-16 | — | — | US | disclosed |
| EP-0178911-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1992-01-22 | — | — | EP | disclosed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | disclosed |
| EP-0178911-A2 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1986-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099061-A1 | SYNTHESIS OF CAROTENOID ANALOGS OR DERIVATIVES WITH IMPROVED ANTIOXIDANT CHARACTERISTICS | CAT, HBZ, POLL | FOLH1 3749/4885SLC6A5 4647/4885CPB2 907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.